We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exercise Training in Sarcoidosis (EXTRAS Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00099424
Recruitment Status : Completed
First Posted : December 14, 2004
Last Update Posted : June 5, 2008
Sponsor:
Information provided by:

Study Description
Brief Summary:

Exercise intolerance and reduced health status have been found in patients with sarcoidosis and has been related to skeletal muscle weakness. The present researchers reason that skeletal muscle weakness is, at least in part, related to physical inactivity and therefore partially reversible following a structured exercise training program. Nevertheless, the effects of exercise training have never been studied in patients with sarcoidosis. Therefore, the present study is undertaken to explore the effects of exercise training in patients with sarcoidosis. A priori, the following hypotheses are formulated:

  • A 12-week exercise training program improves health status, quality of life and exercise capacity in patients with sarcoidosis as compared to sarcoidosis patients without exercise intervention.
  • A 12-week exercise training program improves skeletal muscle function and reduces complaints of anxiety and depression in patients with sarcoidosis as compared to sarcoidosis patients without exercise intervention.
  • A 12-week exercise training program reduces circulating levels of inflammatory markers in patients with sarcoidosis as compared to sarcoidosis patients without exercise intervention.

Condition or disease Intervention/treatment
Sarcoidosis Behavioral: High-intensity exercise training

Detailed Description:
The EXTRAS study is a prospective, randomized, controlled, 24-week crossover clinical trial in which the participants are randomly assigned to receive 12 weeks of dynamic resistance and whole-body endurance exercises followed by 12 weeks without intervention or vice versa. Consenting participants will be assessed at baseline (before randomization, week 0) and at weeks 12 and 24.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Official Title: EXercise TRAining in Sarcoidosis (EXTRAS Study): A Prospective, Randomized, Controlled, Crossover Trial
Study Start Date : February 2004
Estimated Study Completion Date : August 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions


Outcome Measures

Primary Outcome Measures :
  1. Health status: Medical Outcomes Study 36-Item Short-Form Health Survey
  2. Disease-specific quality of life: Sarcoidosis Health Questionnaire
  3. Peak exercise capacity: a symptom-limited peak exercise test on a cycle ergometer
  4. Functional exercise capacity (I): a symptom-limited endurance cycling test at 70% of the achieved peak external load
  5. Functional exercise capacity (II): the distance walked in 6 minutes

Secondary Outcome Measures :
  1. Pulmonary function: forced vital capacity and transfer factor for carbon monoxide
  2. Muscle function: isometric quadriceps femoris muscle peak torque
  3. Systemic inflammation: circulating levels of IL-2, sIL-2r, IL-6, IL-8, TNF-alpha, sTNFR-p55, sTNFR-p75
  4. Anxiety and depression: Hospital Anxiety and Depression Scale
  5. Health-related quality of life (I): Chronic Respiratory Disease Questionnaire
  6. Health-related quality of life (II): St. George's Respiratory Questionnaire

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Main diagnosis: previously diagnosed sarcoidosis according to the latest ATS/ERS/WASOG statement on sarcoidosis (AJRCCM 1999)

Exclusion Criteria:

  • A history of neurosarcoidosis
  • Undergoing structured exercise training at the time of enrollment or in the preceding 6 months
  • Current participation in a pharmacological study
  • Cardiovascular abnormalities on the ECG during baseline peak exercise test
  • A 'normal' baseline peak oxygen uptake (≥90% of the predicted values) in combination with a 'normal' quadriceps peak torque or distance walked in 6 minutes
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00099424


Locations
Belgium
University Hospital Leuven
Leuven, Vlaams-Brabant, Belgium, B-3000
Sponsors and Collaborators
University Hospital, Gasthuisberg
Investigators
Principal Investigator: Martijn A. Spruit, PhD Katholieke Universiteit Leuven
Study Director: Marc Decramer, PhD MD University Hospital, Gasthuisberg
Study Chair: Michiel J. Thomeer, MD University Hospital, Gasthuisberg
More Information

ClinicalTrials.gov Identifier: NCT00099424     History of Changes
Other Study ID Numbers: ML2563
First Posted: December 14, 2004    Key Record Dates
Last Update Posted: June 5, 2008
Last Verified: June 2008

Keywords provided by University Hospital, Gasthuisberg:
exercise training
resistance training
endurance training
Boeck's Sarcoid
Besnier-Boeck Disease

Additional relevant MeSH terms:
Sarcoidosis
Lymphoproliferative Disorders
Lymphatic Diseases